Clinical trial
Trastuzumab and Gefitinib in Treating Patients With Metastatic Breast Cancer
NCT00024154 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00024154 |
|---|---|
| Title | Trastuzumab and Gefitinib in Treating Patients With Metastatic Breast Cancer |
| Official title | A Phase I/II Trial of Herceptin and ZD1839 (Iressa, NSC #715055, IND#61187) in Patients With Metastatic Breast Cancer That Overexpresses HER2/Neu (erbB-2) |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer |
| Intervention type | Biological, Drug, Other |
| Interventions | trastuzumab, gefitinib, laboratory biomarker analysis |
| Enrollment | 132 |
| Start date | Feb 1, 2002 |
| Primary completion | Jul 1, 2007 |
| First posted | Jan 27, 2003 |
| Last update posted | Jan 24, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: